AR and posterior cortical atrophy: Anti-androgenic therapies, including ADT and novel endocrine therapies (Kregel et al., 2013), may enhance the capacity of PCSCs by facilitating the transition of AR+ PCa cells into CSC-like cells (Kanwal et al., 2018; Li et al., 2018), which re-differentiate into neuroendocrine-differentiated subtypes and other AR treatment-resistant subtypes (Verma et al., 2020).